Adrián LLerena MD PhD Professor Clinical Pharmacology
Adrián LLerena MD PhD Professor Clinical Pharmacology
INUBE Biosanitary University Research Institute. University of Extremadura. CICAB Clinical Research
Dirección de correo verificada de unex.es - Página principal
Título
Citado por
Citado por
Año
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 Genotypes and Dosing of Selective Serotonin Reuptake …
JK Hicks, JR Bishop, K Sangkuhl, DJ Müller, Y Ji, SG Leckband, ...
Clinical Pharmacology & Therapeutics 98 (2), 127-134, 2015
5222015
Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test.
L Bertilsson, JA Carrillo, ML Dahl, A Llerena, C Alm, U Bondesson, ...
British journal of clinical pharmacology 38 (5), 471-473, 1994
3481994
Pharmacokinetics of losartan and its metabolite E‐3174 in relation to the CYP2C9 genotype
Ü Yasar, C Forslund‐Bergengren, G Tybring, P Dorado, A LLerena, ...
Clinical Pharmacology & Therapeutics 71 (1), 89-98, 2002
2432002
Relationship between personality and debrisoquine hydroxylation capacity: suggestion of an endogenous neuroactive substrate or product of the cytochrome P4502D6
A Llerena, G Edman, J Cobaleda, J Benitez, D Schalling, L Bertilsson
Acta Psychiatrica Scandinavica 87 (1), 23-28, 1993
1811993
Haloperidol disposition is dependent on debrisoquine hydroxylation phenotype.
A LLerena, C Alm, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (2), 92-97, 1992
1811992
Interethnic variability of CYP2D6 alleles and of predicted and measured metabolic phenotypes across world populations
A LLerena, MEG Naranjo, F Rodrigues-Soares, EM Penas-LLedó, ...
Expert opinion on drug metabolism & toxicology 10 (11), 1569-1583, 2014
1342014
CYP2C9 genotypes and diclofenac metabolism in Spanish healthy volunteers
P Dorado, R Berecz, MJ Norberto, Ü Yasar, ML Dahl, A LLerena
European journal of clinical pharmacology 59 (3), 221-225, 2003
1232003
Disposition of clozapine in man: lack of association with debrisoquine and S‐mephenytoin hydroxylation polymorphisms.
ML Dahl, A Llerena, U Bondesson, L Lindstrom, L Bertilsson
British journal of clinical pharmacology 37 (1), 71-74, 1994
1211994
Pharmacogenomic information in drug labels: European Medicines Agency perspective
F Ehmann, L Caneva, K Prasad, M Paulmichl, M Maliepaard, A Llerena, ...
The pharmacogenomics journal 15 (3), 201-210, 2015
1182015
Interethnic differences in drug metabolism: influence of genetic and environmental factors on debrisoquine hydroxylation phenotype
A Llerena, J Cobaleda, C Martinez, J Benitez
European journal of drug metabolism and pharmacokinetics 21 (2), 129-138, 1996
1151996
Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.
A LLerena, ML Dahl, B Ekqvist, L Bertilsson
Therapeutic drug monitoring 14 (3), 261-264, 1992
1121992
Pharmacogenomics education: International Society of Pharmacogenomics recommendations for medical, pharmaceutical, and health schools deans of education
D Gurwitz, JE Lunshof, G Dedoussis, CS Flordellis, U Fuhr, J Kirchheiner, ...
The pharmacogenomics journal 5 (4), 221-225, 2005
1082005
QTc interval, CYP2D6 and CYP2C9 genotypes and risperidone plasma concentrations
A Llerena, R Berecz, P Dorado, A de la Rubia
Journal of psychopharmacology 18 (2), 189-193, 2004
922004
Lower frequency of CYP2C9* 2 in Mexican-Americans compared to Spaniards
A Llerena, P Dorado, F O'kirwan, R Jepson, J Licinio, ML Wong
The pharmacogenomics journal 4 (6), 403-406, 2004
872004
Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients
JA Carrillo, SI Ramos, AG Herraiz, A Llerena, JAG Agundez, R Berecz, ...
Journal of clinical psychopharmacology 19 (6), 494-499, 1999
871999
Development of a PCR-based strategy for CYP2D6 genotyping including gene multiplication of worldwide potential use
P Dorado, MC Cáceres, E Pozo-Guisado, ML Wong, J Licinio, A LLerena
Biotechniques 39 (10 Suppl), S571-S754, 2005
852005
CYP2D6 genotype and debrisoquine hydroxylation phenotype in Cubans and Nicaraguans
A Llerena, P Dorado, R Ramírez, I González, M Alvarez, EM Peñas-Lledó, ...
The Pharmacogenomics Journal 12 (2), 176-183, 2012
842012
Pharmacogenetics of debrisoquine and its use as a marker for CYP2D6 hydroxylation capacity
A LLerena, P Dorado, EM Peñas-Lledó
Future Medicine Ltd 10 (1), 17-28, 2009
842009
Assessing clinical and functional outcomes in a gene–environment interaction study in first episode of psychosis (PEPs)
M Bernardo, M Bioque, M Parellada, JS Ruiz, MJ Cuesta, A Llerena, ...
Revista de Psiquiatría y Salud Mental (English Edition) 6 (1), 4-16, 2013
822013
Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers
I González, EM Peñas-Lledó, B Pérez, P Dorado, M Álvarez, A LLerena
Future Medicine Ltd 9 (7), 833-840, 2008
822008
El sistema no puede realizar la operación en estos momentos. Inténtalo de nuevo más tarde.
Artículos 1–20